Economic evaluation of vedolizumab SC for the treatment of moderate-to-severe ulcerative colitis in Canada

被引：0
作者：
Fischer, A. [1 ]
Oppe, M. [2 ]
Stypa, S. [1 ]
Lukyanov, V. [3 ]
Petrakis, I. [4 ]
机构：
[1] Takeda Canada Inc, Patient Value & Access, Toronto, ON, Canada
[2] Axent Solut, Pharmacoecon, San Cristobal la Laguna, Spain
[3] IQVIA, Real World Insights, Amsterdam, Netherlands
[4] Takeda Inc, Payer Value & Patient Access, Boston, MA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P424
引用
收藏
页码：S387 / S387
页数：1
相关论文
共 50 条
[31]   Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis [J].
Cristina Trigo-Vicente ;
Vicente Gimeno-Ballester ;
Santiago García-López ;
Alejandro López-Del Val .
International Journal of Clinical Pharmacy, 2018, 40 :1411-1419
[32]   Sustained corticosteroid-free remission with vedolizumab in moderate-to-severe ulcerative colitis: A post hoc analysis of GEMINI 1 [J].
Loftus, E. V. ;
Sands, B. E. ;
Colombel, J. -F. ;
Dotan, I. ;
Khalid, J. M. ;
Tudor, D. ;
Geransar, P. .
JOURNAL OF CROHNS & COLITIS, 2018, 12 :S317-S318
[33]   Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis [J].
Yokomizo, Lauren ;
Limketkai, Berkeley ;
Park, K. T. .
BMJ OPEN GASTROENTEROLOGY, 2016, 3 (01)
[34]   Efficacy of tofacitinib for the treatment of moderate-to-severe ulcerative colitis: real-world data [J].
Xiao, Y. ;
Lakatos, P. L. ;
Bourdages, R. ;
Bitton, A. ;
Afif, W. ;
Kohen, R. ;
Berberi, M. ;
Bessissow, T. .
JOURNAL OF CROHNS & COLITIS, 2020, 14 :S445-S445
[35]   CLINICAL AND HEALTH OUTCOMES ASSOCIATED WITH DIFFERENT TREATMENT SEQUENCES FOR MODERATE-TO-SEVERE ULCERATIVE COLITIS [J].
Paul, D. ;
Biswas, S. ;
Cato, M. ;
Ambavane, A. .
VALUE IN HEALTH, 2024, 27 (06) :S118-S118
[36]   Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe [J].
Armuzzi, Alessandro ;
DiBonaventura, Marco daCosta ;
Tarallo, Miriam ;
Lucas, James ;
Bluff, Daniel ;
Hoskin, Benjamin ;
Bargo, Danielle ;
Cappelleri, Joseph C. ;
Quirk, Daniel ;
Salese, Leonardo .
PLOS ONE, 2020, 15 (01)
[37]   Treatment Patterns Among Moderate-to-Severe Ulcerative Colitis Patients in TARGET-IBD [J].
Cohen, Benjamin ;
Click, Benjamin ;
Barnes, Edward ;
Ungaro, Ryan ;
Gupte-Singh, Komal ;
Kumar, Jinender ;
Lawlor, Garrett ;
Canavan, James ;
Crawford, Julie ;
Munoz, Breda ;
Perez, Anthony ;
Morris, Heather ;
Long, Millie ;
Sands, Bruce .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (12) :S5-S5
[38]   Treatment Patterns Among Moderate-to-Severe Ulcerative Colitis Patients in TARGET-IBD [J].
Cohen, Benjamin ;
Click, Benjamin ;
Barnes, Edward ;
Ungaro, Ryan ;
Gupte-Singh, Komal ;
Kumar, Jinender ;
Lawlor, Garrett ;
Canavan, James ;
Crawford, Julie ;
Munoz, Breda ;
Perez, Anthony ;
Morris, Heather ;
Long, Millie ;
Sands, Bruce .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 :S5-S5
[39]   SUSTAINED CORTICOSTEROID-FREE REMISSION WITH VEDOLIZUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS: A POST HOC ANALYSIS OF GEMINI 1 [J].
Loftus, Edward V. ;
Sands, Bruce E. ;
Colombel, Jean Frederic ;
Dotan, Iris ;
Khalid, Javaria M. ;
Tudor, David ;
Geransar, Parnia .
GASTROENTEROLOGY, 2018, 154 (06) :S390-S390
[40]   Vedolizumab for the treatment of ulcerative colitis [J].
Stallmach, Andreas ;
Schmidt, Carsten ;
Teich, Niels .
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (02) :165-175
12345